Research Article

The AAPS Journal

, Volume 12, Issue 4, pp 576-585

Ligand-Binding Mass Spectrometry to Study Biotransformation of Fusion Protein Drugs and Guide Immunoassay Development: Strategic Approach and Application to Peptibodies Targeting the Thrombopoietin Receptor

  • Michael P. HallAffiliated withDepartment of PKDM, Amgen Inc.
  • , Colin GeggAffiliated withDepartment of Protein Science, Amgen Inc.
  • , Kenneth WalkerAffiliated withDepartment of Protein Science, Amgen Inc.
  • , Christopher SpahrAffiliated withDepartment of Protein Science, Amgen Inc.
  • , Robert OrtizAffiliated withDepartment of PKDM, Amgen Inc.
  • , Vimal PatelAffiliated withDepartment of PKDM, Amgen Inc.
  • , Steven YuAffiliated withDepartment of PKDM, Amgen Inc.
  • , Liana ZhangAffiliated withDepartment of PKDM, Amgen Inc.
  • , Hsieng LuAffiliated withDepartment of Protein Science, Amgen Inc.
    • , Binodh DeSilvaAffiliated withDepartment of PKDM, Amgen Inc.
    • , Jean W. LeeAffiliated withDepartment of PKDM, Amgen Inc. Email author 

Abstract

The knowledge of in vivo biotransformation (e.g., proteolysis) of protein therapeutic candidates reveals structural liabilities that impact stability. This information aids the development and confirmation of ligand-binding assays with the required specificity for bioactive moieties (including intact molecule and metabolites) for appropriate PK profiling. Furthermore, the information can be used for re-engineering of constructs to remove in vivo liabilities in order to design the most stable candidates. We have developed a strategic approach of ligand-binding mass spectrometry (LBMS) to study biotransformation of fusion proteins of peptides fused to human Fc (“peptibodies”) using anti-human Fc immunoaffinity capture followed by tiered mass spectrometric interrogation. LBMS offers the combined power of selectivity of ligand capture with the specificity and detailed molecular-level information of mass spectrometry. In this paper, we demonstrate the preclinical application of LBMS to three peptibodies, AMG531 (romiplostim), AMG195(linear), and AMG195(loop), that target the thrombopoietin receptor. The data show that ligand capture offers excellent sample cleanup and concentration of intact peptibodies and metabolites for subsequent query by matrix-assisted laser desorption ionization time-of-flight mass spectrometry for identification of in vivo proteolytic points. Additional higher-resolution analysis by nanoscale liquid chromatography interfaced with electrospray ionization mass spectrometry is required for identification of heterogeneous metabolites. Five proteolytic points are accurately identified for AMG531 and two for AMG195(linear), while AMG195(loop) is the most stable construct in rats. We recommend the use of LBMS to assess biotransformation and in vivo stability during early preclinical phase development for all novel fusion proteins.

Key words

fusion protein biotransformation in vivo stability of biopharmaceuticals immunoaffinity-mass spectrometry ligand-binding assay peptibodies